Pharmaceutical product permissions

A searchable record of what Walter is equipped to evaluate.

Explore compositions across oral solids, oral liquids, sterile injectables, topical formats and selected specialist presentations. Use the catalogue to begin a technical and commercial discussion—not as a substitute for written facility-specific confirmation.

5,500Distinct records
21Dosage forms
407Sterile injectable records
17Therapeutic indexes

Built for portfolio teams

Move from a molecule search to a focused feasibility conversation.

The catalogue brings together composition, strength, pharmacological class, dosage form, manufacturing stream, BCS class and documented regulatory references. It also incorporates products listed in Walter’s March 2025 Injectables Manufacturing Profile. Therapeutic and pharmacological classes are practical navigation labels; final indication, regulatory position and site suitability are confirmed product by product.

Search the catalogue

Selected catalogue briefs

Explore a composition for your manufacturing brief.

Browse selected compositions by dosage form, then share the required strength, pack, quantities and target market for a product-specific feasibility review.

Search the full catalogue
Browse 26 selected composition briefs

Therapeutic index

Begin with the treatment area.

Each composition is assigned to one practical primary area for navigation. Combination products may span more than one clinical use and remain subject to product-specific review.

Searchable permissions catalogue

Find a composition, dosage form or capability route.

5,500distinct permission records

Loading full catalogue search…
Therapeutic area
Dosage-form family
Specific dosage form
Pharmacological class
Manufacturing stream
BCS classification
Confirmed CDSCO category
Drugs Rules status

24 records shown

Dermatology & topical carePRM 5585
Dosage formTopical cream
Topical

/ 15 gm, Clobetasol Propionate 0.5% w/w, Iodochlorhydroxyquinoline 1% w/w, Ketoconazole 2% w/w, Neomycin 0.1% w/w, Tolnaftate 1% w/w

Route
Topical
Formulation type
Topical semi-solid cream
Pharmacological class
Aminoglycoside antibiotic + Azole antifungal + Corticosteroid + Hydroxyquinoline antimicrobial + Thiocarbanilate antifungal
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 5593
Dosage formTopical gel
Topical

Absolute Alcohol 50 mg, Menthol 50 mg, Methyl Salicylate 100 mg, Thiocolchicoside 0.25% w/w

Route
Topical
Formulation type
Topical semi-solid gel
Pharmacological class
Counterirritant / topical analgesic + Skeletal muscle relaxant
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 2153
Dosage formHard-gelatin capsules
Oral

Acitretin 10 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Topical dermatological agent
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 2154
Dosage formHard-gelatin capsules
Oral

Acitretin 25 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Topical dermatological agent
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 5598
Dosage formTopical ointment
Topical

Acyclovir 3%

Route
Topical
Formulation type
Topical semi-solid ointment
Pharmacological class
Antiviral
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 5599
Dosage formTopical ointment
Topical

Acyclovir 5%

Route
Topical
Formulation type
Topical semi-solid ointment
Pharmacological class
Antiviral
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 5990
Dosage formTopical cream
Topical

Aloe Vera Extract 10% w/v, D-Panthenol 0.5% w/v, Glycerine 2% w/v, Ketoconazole 1% w/v, Niacinamide 1% w/v, Vitamin E Acetate 0.5% w/v

Route
Topical
Formulation type
Topical semi-solid cream
Pharmacological class
Azole antifungal
Manufacturing stream
Cosmetic
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 5600
Dosage formTopical ointment
Topical

Alpha Chymotrypsin 60 mg, Ethyl Nicotinate 200 mg / 20 gm

Route
Topical
Formulation type
Topical semi-solid ointment
Pharmacological class
Anti-inflammatory proteolytic enzyme
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 2790
Dosage formTablets
Oral

Apremilast 10 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
PDE4 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 2791
Dosage formTablets
Oral

Apremilast 20 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
PDE4 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 2792
Dosage formTablets
Oral

Apremilast 30 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
PDE4 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 5601
Dosage formTopical ointment
Topical

Bacitracin Zinc 500 IU, Gram Of - Neomycin Sulphate 5 mg

Route
Topical
Formulation type
Topical semi-solid ointment
Pharmacological class
Aminoglycoside antibiotic + Topical antibiotic
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 1415
Dosage formTopical cream
Topical

Beclomethasone Dipropionate 0.025% w/v, Clotrimazole 1% w/v, Neomycin Sulphate 0.5% w/v

Route
Topical
Formulation type
Topical semi-solid cream
Pharmacological class
Antifungal
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 1416
Dosage formTopical cream
Topical

Beclomethasone Dipropionate 0.025% w/w, Chlorocresol 0.1% w/w, Clotrimazole 1% w/w, Neomycin Sulphate 0.5% w/w

Route
Topical
Formulation type
Topical semi-solid cream
Pharmacological class
Antifungal
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 1417
Dosage formTopical cream
Topical

Beclomethasone Dipropionate, Ketoconazole 2% w/w

Route
Topical
Formulation type
Topical semi-solid cream
Pharmacological class
Antifungal
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 1394
Dosage formTopical gel
Topical

Benzalkonium Chloride 0.01% w/w, Choline Salicylate 8.7% w/w, Lignocaine 2% w/w

Route
Topical
Formulation type
Topical semi-solid gel
Pharmacological class
Topical dermatological agent
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 5602
Dosage formTopical ointment
Topical

Benzoic Acid 10% w/w, Boric Acid 05% w/w, Salicylic Acid 10% w/w

Route
Topical
Formulation type
Topical semi-solid ointment
Pharmacological class
Keratolytic / topical antifungal
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 5603
Dosage formTopical ointment
Topical

Benzoic Acid 9.95% w/w, Salicylic Acid 10% w/w, Thymol 0.5% w/w

Route
Topical
Formulation type
Topical semi-solid ointment
Pharmacological class
Keratolytic / topical antifungal
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 5604
Dosage formTopical ointment
Topical

Benzyl Alcohol 0.1% w/w, Carboxymethylcellulose Sodium 0.3% w/w, Glycerin 1% w/w

Route
Topical
Formulation type
Topical semi-solid ointment
Pharmacological class
Ophthalmic lubricant / tear substitute
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 5605
Dosage formTopical ointment
Topical

Benzyl Alcohol 1.00% w/w, Diclofenac Sodium 1.00% w/w, Menthol 5% w/w, Mephenesin 5% w/w, Methyl Salicylate 5% w/w, Oleum Lini (Containing Predominantly Linolenic Acid) 3% w/w

Route
Topical
Formulation type
Topical semi-solid ointment
Pharmacological class
Counterirritant / topical analgesic + NSAID analgesic + Skeletal muscle relaxant
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 5594
Dosage formTopical gel
Topical

Benzyl Alcohol 1% w/w, Diclofenac Diethylamine 1.16% w/w, Linseed Oil 3% w/w, Menthol 5% w/w, Methyl Salicylate 10% w/w / gm

Route
Topical
Formulation type
Topical semi-solid gel
Pharmacological class
Counterirritant / topical analgesic + NSAID analgesic
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 5595
Dosage formTopical gel
Topical

Benzyl Alcohol 1% w/w, Diclofenac Diethylamine 1.16% w/w, Menthol 5% w/w, Methyl Salicylate 10%w/w, Oleum Lini 3% w/w

Route
Topical
Formulation type
Topical semi-solid gel
Pharmacological class
Counterirritant / topical analgesic + NSAID analgesic
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 1807
Dosage formLiquid injectables
Parenteral

Betamethasone 4 mg

Route
Parenteral
Formulation type
Sterile liquid injectable
Pharmacological class
Topical dermatological agent
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Parenteral
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 0248
Dosage formTablets
Oral

Betamethasone Sodium Phosphate 0.5 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Topical dermatological agent
Manufacturing stream
Non-beta-lactam
BCS class
Not specified
Drugs Rules status
Schedule HList or category match
CDSCO categoryNew Drug
Documented match

Listed in CDSCO New Drug approval records

CDSCO filing reference · page 870

Explore the product catalogue

Browse product pages by therapeutic area.

Browse compositions, strengths and dosage forms for third-party and contract manufacturing enquiries. Each product page includes its catalogue specification, manufacturing and packaging considerations, and a product-specific enquiry link. Confirm the applicable unit, documents and commercial terms with Walter.

How to read this catalogue

Permission is a starting point—not a supply commitment.

01

Therapeutic index

Primary areas provide buyer-friendly navigation. Combination products may reasonably sit across several clinical categories.

02

Facility confirmation

Current licence scope, site allocation, equipment fit and applicable segregation requirements are checked before commitment.

03

Product feasibility

Formula, strength, presentation, pack, target market, testing requirements and commercial scale are assessed together.

04

Responsible use

This B2B catalogue is not prescribing information, patient guidance or a representation that every composition is currently available for sale.

Start the conversation

Found a composition worth discussing?

Use the enquiry link on any record to carry its composition and dosage form into your manufacturing brief.

Request a quote
Quick chat on WhatsAppLet’s discuss your product